Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,102 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard-of-care (SoC) Clear all
Terminated Phase 3 Interventional Results available

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

NCT04734873
View directory record Official record
Conditions
Covid-19
Interventions
CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC, Placebo + SOC
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
13
States / cities
Chula Vista, California • El Centro, California • La Mesa, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 3, 2026, 10:58 AM EDT
Completed Not applicable Interventional Results available

The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM)

NCT04410146
View directory record Official record
Conditions
Subdural Hematoma, Chronic
Interventions
SQUID Embolization, SQUID Embolization and Surgical Evacuation, Surgical Evacuation, Standard Medical Management
Device · Procedure · Other
Lead sponsor
Balt USA
Industry
Eligibility
30 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Riverside, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 3, 2026, 10:58 AM EDT
Suspended Phase 3 Interventional

Methadone as an Alternative Treatment for Children Underdoing HSCT

NCT06940570
View directory record Official record
Conditions
Leukemia, Aplastic Anemia, Bone Marrow Failure Syndromes, SCID
Interventions
PCA plus methadone (Experimental), PCA Alone (SOC)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 3, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

NCT03830866
View directory record Official record
Conditions
Locally Advanced Cervical Cancer
Interventions
Durvalumab, Cisplatin, Carboplatin, external beam radiation therapy (EBRT) + brachytherapy
Biological · Drug · Radiation
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 3, 2026, 10:58 AM EDT
Recruiting Phase 2 Interventional

High Dose Albumin in Refractory Ascites

NCT05867602
View directory record Official record
Conditions
Ascites
Interventions
Albumin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 3, 2026, 10:58 AM EDT
Not yet recruiting Phase 2 Interventional

Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin

NCT07815704
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer, High Grade Serous Adenocarcinoma of Ovary
Interventions
Standard of Care + atorvastatin, Standard of Care (SOC)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 3, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional Results available

Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization

NCT01399593
View directory record Official record
Conditions
Antibody Mediated Rejection
Interventions
Eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
17
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Oct 3, 2026, 10:58 AM EDT
Recruiting Not applicable Interventional

Impact of a Telerehabilitation Program With Technology Enhancement on Post-burn Recovery

NCT06162052
View directory record Official record
Conditions
Burns
Interventions
Tele-Rehabilitation
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 3, 2026, 10:58 AM EDT
Not listed No phase listed Observational

Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort

NCT05295277
View directory record Official record
Conditions
Developmental Disability, Intellectual Disability, Autism Spectrum Disorder, Congenital Anomaly, Fragile X Syndrome, Facioscapulohumeral Muscular Dystrophy 1
Interventions
Standard of care genetic testing group
Other
Lead sponsor
Bionano Genomics
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Atlanta, Georgia • Augusta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 3, 2026, 10:58 AM EDT
Completed Phase 4 Interventional Results available

Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection

NCT04340557
View directory record Official record
Conditions
SARS-CoV Infection
Interventions
Losartan
Drug
Lead sponsor
Sharp HealthCare
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 3, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study

NCT05545150
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Bilateral Breast Carcinoma, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8
Interventions
Intraoperative Imaging, Lumpectomy
Procedure · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Chicago, Illinois • Lexington, Kentucky • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 3, 2026, 10:58 AM EDT
Recruiting Not applicable Interventional

A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial

NCT07074756
View directory record Official record
Conditions
Glioma, Recurrent Glioma, Recurrent Glioblastoma
Interventions
Chemotherapy, Computed Tomography, Internet-Based Intervention, Magnetic Resonance Imaging, Neurologic Examination, Questionnaire Administration, Surveillance, Propranolol, Imipramine, Bevacizumab
Drug · Procedure · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 3, 2026, 10:58 AM EDT
Withdrawn Phase 2 Interventional

LACTYFERRIN™ Forte and ZINC Defense™ and Standard of Care (SOC) vs SOC in the Treatment of Non-hospitalized Patients With COVID-19

NCT05783180
View directory record Official record
Conditions
COVID-19
Interventions
Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™, Placebo
Drug
Lead sponsor
Jose David Suarez, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 3, 2026, 10:58 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting

NCT07210125
View directory record Official record
Conditions
HIV
Interventions
Lenacapavir long-acting, Standard of Care (SOC)
Drug · Other
Lead sponsor
Kelley-Ross & Associates, Inc.
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 3, 2026, 10:58 AM EDT
Recruiting Not applicable Interventional

INNOVEN: Efficacy of Porcine Placental Extracellular Matrix Plus Standard of Care (SOC) Versus SOC Alone

NCT06606210
View directory record Official record
Conditions
Wound Heal, Venous Leg Ulcer
Interventions
InnovaMatrix® AC
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
North Port, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 3, 2026, 10:58 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

NCT03607643
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
Interventions
Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide
Drug
Lead sponsor
Leaf Vertical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 3, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1

NCT05553808
View directory record Official record
Conditions
Neoplasms
Interventions
Docetaxel, Feladilimab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
St Louis, Missouri • Nashville, Tennessee • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 3, 2026, 10:58 AM EDT
Recruiting Phase 3 Interventional

a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers

NCT07852338
View directory record Official record
Conditions
Diabetic Foot Ulcer, Amniotic Membrane Placental Allograft, Biologic
Interventions
All sentinel cohort participants will receive biologic plus SOC. who receive at least one treatment of the biologic plus SOC and complete the treatment period of 12 weeks., Standard wound care for diabetic foot ulcers, Participants in the randomized phase are assigned by randomization (2:1) to BIOxHEAL plus SOC or SOC alone. once weekly for up to 12 weeks or until complete ulcer closure
Biological · Other
Lead sponsor
Applied Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boardman, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 3, 2026, 10:58 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

NCT07023289
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Telisotuzumab Adizutecan, Standard of Care
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 3, 2026, 10:58 AM EDT
Recruiting Not applicable Interventional

Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers

NCT06681428
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers
Interventions
Allograft
Other
Lead sponsor
Tides Medical
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Fresno, California • Los Angeles, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 3, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

NCT05240898
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
RO7623066, Olaparib, Carboplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Orange, California • New Haven, Connecticut • Detroit, Maine + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 3, 2026, 10:58 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone

NCT05519007
View directory record Official record
Conditions
Joint Infection
Interventions
No-Rinse Solution (NS), Saline irrigation
Other
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
936 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
Manhasset, New York • New Hyde Park, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 3, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

Study of GS-3242 in Participants With HIV-1; Substudy-05

NCT07001319
View directory record Official record
Conditions
HIV-1-infection
Interventions
GS-3242, BVY, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Bakersfield, California • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 3, 2026, 10:58 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

BTX-A Treatment for Palmar Hyperhidrosis

NCT01262339
View directory record Official record
Conditions
Primary Focal Hyperhidrosis of the Hands
Interventions
BTX-A
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
16 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 3, 2026, 10:58 AM EDT